Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV.

[1]  B..  Antiviral therapy of chronic hepatitis , 2017 .

[2]  J. Hauber,et al.  CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X , 2015, Scientific Reports.

[3]  T. Block,et al.  Chronic hepatitis B: A wave of new therapies on the horizon. , 2015, Antiviral research.

[4]  Xiangmei Chen,et al.  Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. , 2015, World journal of gastroenterology.

[5]  Yu Chen,et al.  Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. , 2015, The Journal of general virology.

[6]  Wolfgang Wurst,et al.  Development of an intein-mediated split–Cas9 system for gene therapy , 2015, Nucleic acids research.

[7]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[8]  Chunsheng Dong,et al.  Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. , 2015, Antiviral research.

[9]  David A. Scott,et al.  CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015, Scientific Reports.

[10]  K. Khalili,et al.  The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. , 2015, Discovery medicine.

[11]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[12]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[13]  J. Fu,et al.  Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus , 2015, Gene Therapy.

[14]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[15]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[16]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[17]  Simon L. Bullock,et al.  Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila , 2014, Proceedings of the National Academy of Sciences.

[18]  David R. Liu,et al.  Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification , 2014, Nature Biotechnology.

[19]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[20]  C. Rice,et al.  Getting Rid of a Persistent Troublemaker to Cure Hepatitis , 2014, Science.

[21]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[22]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[23]  Qi Zhou,et al.  Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems , 2013, Nature Biotechnology.

[24]  Botao Zhang,et al.  Efficient genome editing in plants using a CRISPR/Cas system , 2013, Cell Research.

[25]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[26]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  George M. Church,et al.  Heritable genome editing in C. elegans via a CRISPR-Cas9 system , 2013, Nature Methods.

[28]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[29]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[30]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[31]  Feng Zhang,et al.  CRISPR-assisted editing of bacterial genomes , 2013, Nature Biotechnology.

[32]  Jeffry D. Sander,et al.  Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.

[33]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[34]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[35]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[36]  Joshua T. Schiffer,et al.  Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections , 2012, Journal of Virology.

[37]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[38]  J. Vogel,et al.  CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III , 2011, Nature.

[39]  M. Yuen,et al.  Treatment of chronic hepatitis B: Evolution over two decades , 2011, Journal of gastroenterology and hepatology.

[40]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[41]  Anton P. McCaffrey,et al.  Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  K. Lee.  Antiviral Therapy for Chronic Hepatitis B , 2009 .

[43]  G. Carosi,et al.  Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. , 2009, Journal of hepatology.

[44]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[45]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[46]  M. Feitelson,et al.  Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. , 2007, Cancer letters.

[47]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[48]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[49]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[50]  R. Jordan,et al.  Molecular viral oncology of hepatocellular carcinoma , 2003, Oncogene.

[51]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[52]  M. Wick,et al.  Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection , 1993, Hepatology.

[53]  H. Varmus,et al.  The molecular biology of the hepatitis B viruses. , 1987, Annual review of biochemistry.

[54]  P. Pontisso,et al.  Detection of hepatitis B virus DNA in mononuclear blood cells. , 1984, British medical journal.

[55]  A. Dejean,et al.  Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. , 1984, The Journal of general virology.